Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1996-01-23
2002-04-02
Brusca, John S. (Department: 1631)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100, C435S320100, C536S023400
Reexamination Certificate
active
06365344
ABSTRACT:
TECHNICAL FIELD
The technical field of this invention is methods for screening for transdominant effector peptides and RNA molecules selected inside living cells from randomized pools.
BACKGROUND
Signaling pathways in cells often begin with an effector stimulus that leads to a phenotypically describable change in cellular physiology. Despite the key role intracellular signaling pathways play in pathogenesis, in most cases, little is understood about a signaling pathway other than the initial stimulus and the ultimate cellular response.
Historically, signal transduction has been analyzed by biochemistry or genetics. The biochemical approach dissects a pathway in a “stepping-stone” fashion: find a molecule that acts at, or is involved in, one end of the pathway, isolate assayable quantities and then try to determine the next molecule in the pathway, either upstream or downstream of the isolated one. The genetic approach is classically a “shot in the dark”: induce or derive mutants in a signaling pathway and map the locus by genetic crosses or complement the mutation with a cDNA library. Limitations of biochemical approaches include a reliance on a significant amount of pre-existing knowledge about the constituents under study and the need to carry such studies out in vitro, post-mortem. Limitations of purely genetic approaches include the need to first derive and then characterize before proceeding with identifying and cloning the gene.
Screening molecular libraries of chemical compounds for drugs that regulate signaling systems has led to important discoveries of great clinical significance. Cyclosporin A (CsA) and FK506, for examples, were selected in standard pharmaceutical screens for inhibition of T-cell activation. It is noteworthy that while these two drugs bind completely different cellular proteins—cyclophilin and FK506 binding protein (FKBP), respectively, the effect of either drug is virtually the same—profound and specific suppression of T-cell activation, phenotypically observable in T cells as inhibition of mRNA production dependent on transcription factors such as NF-AT and NF-&kgr;B. Libraries of small peptides have also been successfully screened in assays for bioactivity. The literature is replete with examples of small peptides capable of modulating a wide variety of signaling pathways. For example, a peptide derived from the HIV- 1 envelope protein has been shown to block the action of cellular calmodulin.
A major limitation of conventional in vitro screens is delivery. While only minute amounts of an agent may be necessary to modulate a particular cellular response, delivering such an amount to the requisite subcellular location necessitates exposing the target cell or system to relatively massive concentrations of the agent. The effect of such concentrations may well mask or preclude the targeted response.
The present invention provides methods and compositions to create, effectively introduce into cells and screen compounds that affect a signaling pathway. Little or no knowledge of the pathway is required, other than a presumed signaling event and an observable physiologic change in the target cell. The disclosed methods are conceptually distinct from prior library search methods in that it is an in vivo stratagem for accessing intracellular signaling mechanisms. The invention also provides for the isolation of the constituents of the pathway, the tools to characterize the pathway, and lead compounds for pharmaceutical development.
Relevant Literature
Mann et al. (1983) Cell 33, 153-159, Pear et al. (1993) Proc. Natl. Acad. Sci. USA 90(18):8392-6 and copending U.S. patent application Ser. No. 08/023,909 describe the BOSC and BING retroviral systems useful as delivery vectors for the disclosed methods.
Scott and Craig (1994) Current Opinion in Biotechnology 5:40-48 review random peptide libraries. Hupp et al. (1995) describe small peptides which activate the latent sequence-specific DNA binding function of p53. Palzkill et al. (1994) report the selection of functional signal cleavage sites from a library of random sequences introduced into TEM-1-lactamase.
SUMMARY OF THE INVENTION
The invention provides methods and compositions for screening for transdominant intracellularly bioactive agents such as pharmaceuticals. The invention accesses molecules or targets within living cells and provides for the direct selection of those bioactive agents with desired phenotypic effects. The general methods involve steps: expressing a molecular library of randomized nucleic acids as a plurality of isolated corresponding randomized expression products in a plurality of cells, each of the nucleic acids comprising a different nucleotide sequence, screening for a cell of the plurality of cells exhibiting a changed physiology in response to the presence in the cell of a transdominant expression product of the corresponding expression products; and detecting and isolating the cell and/or transdominant expression product,
In a particular embodiment, the expressing step comprises translating the nucleic acids and/or corresponding transcripts, and each of the nucleic acids encodes a peptide comprising a different amino acid sequence. The nucleic acids may be joined to sequences encoding polypeptide backbones of artificial design capable of intracellularly presenting randomized peptides as structured domains. The methods may also involve introducing the library into the cells, such as through the use of retroviral vectors, and particularly suitable vectors are also disclosed.
REFERENCES:
patent: 5217889 (1993-06-01), Roninson et al.
patent: 5223408 (1993-06-01), Goeddel
patent: 5283173 (1994-02-01), Fields et al.
patent: 5639595 (1997-06-01), Mirabelli et al.
patent: 5723287 (1998-03-01), Russell
patent: 6153380 (2000-11-01), Nolan et al.
patent: 0334301 (1989-09-01), None
patent: 0 383 620 (1990-08-01), None
patent: 86/05803 (1986-10-01), None
patent: 90/02809 (1990-03-01), None
patent: 91/17266 (1991-11-01), None
patent: 91/19818 (1991-12-01), None
patent: 92/05266 (1992-04-01), None
patent: 92/07071 (1992-04-01), None
patent: 93/08278 (1993-04-01), None
patent: 93/23569 (1993-11-01), None
patent: 94/06920 (1994-03-01), None
patent: 94/19478 (1994-09-01), None
patent: 95/04824 (1995-02-01), None
patent: 95/16054 (1995-06-01), None
patent: 96/23899 (1996-08-01), None
patent: 96/38553 (1996-12-01), None
patent: 96/40987 (1996-12-01), None
patent: 00/05406 (2000-02-01), None
Rayner and Gonda, “A Simple and Efficient Procedure for Generating Stable Expression Libraries by cDNA Cloning in a Retroviral Vector,”Mol Cell Biol14(2):880-887 (Feb. 1994).
Gudkov et al., “Cloning mammalian genes by expression selection of genetic suppressor elements: Association of kinesin with drug resistance and cell immortalization,”Proc. Natl. Acad. Sci. USA91:3744-3748 (Apr. 1994).
Whiteway et al., “Dominant negative selection heterologous genes: Isolation ofCandida albicansgenes that interfere withSaccharomyces cervisiaemating factor-induced cell cycle arrest,”Proc. Natl. Acad. Sci. USA89:9410-9414 (Oct. 1992).
Roninson et al., “Genetic Suppressor Elements: New Tools for Molecular Oncology—Thirteenth Cornelius P. Rhoads Memorial Award Lecture,”Cancer Res55:4023-4028 (Sep. 1995).
Murphy and Efstratiadis, “Cloning vectors for expression of cDNA libraries in mammalian cells,”Proc. Natl. Acad. Sci. USA84:8277-8281 (Dec. 1987).
LaBean and Kauffman, “Design of synthetic gene libraries encoding random sequence proteins with desired ensemble characteristics,”Protein Science2:1249-1254 (1993).
Deng et al., “Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries,”Proc. Natl. Acad. Sci. USA92:4992-4996 (May 1995).
Virnekäs et al., “Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis,”Nucleic Acids Res22(25):5600-5607 (1994).
Ito et al., “A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction,”Gene102:67-70 (1991).
Stuhlmann et al., “Introduction o
Nolan Garry P.
Rothenberg S. Michael
Brusca John S.
Flehr Hohbach Test Albritton & Herbert LLP
Shyjan Anne M.
Silva Robin M.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Methods for screening for transdominant effector peptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for screening for transdominant effector peptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for screening for transdominant effector peptides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2867179